{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu L"],"funding":["NCI NIH HHS","U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","Cancer Prevention and Research Institute of Texas"],"pagination":["5902"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7677397"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["CAR-T cell therapy is effective for hematologic malignancies. However, considerable numbers of patients relapse after the treatment, partially due to poor expansion and limited persistence of CAR-T cells in vivo. Here, we demonstrate that human CAR-T cells polarized and expanded under a Th9-culture condition (T9 CAR-T) have an enhanced antitumor activity against established tumors. Compared to IL2-polarized (T1) cells, T9 CAR-T cells secrete IL9 but little IFN-γ, express central memory phenotype and lower levels of exhaustion markers, and display robust proliferative capacity. Consequently, T9 CAR-T cells mediate a greater antitumor activity than T1 CAR-T cells against established hematologic and solid tumors in vivo. After transfer, T9 CAR-T cells migrate effectively to tumors, differenti"],"journal":["Nature communications"],"pubmed_title":["Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9."],"pmcid":["PMC7677397"],"funding_grant_id":["R01 CA211073","R01 CA239255","R01 CA200539","R01 CA214811","RR180044"],"pubmed_authors":["Ye L","Qian J","Bi E","Liu L","Wang Q","Xiao L","Su P","Lu Y","Yang M","Ma X","Yi Q","Xiong W"],"additional_accession":[]},"is_claimable":false,"name":"Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9.","description":"CAR-T cell therapy is effective for hematologic malignancies. However, considerable numbers of patients relapse after the treatment, partially due to poor expansion and limited persistence of CAR-T cells in vivo. Here, we demonstrate that human CAR-T cells polarized and expanded under a Th9-culture condition (T9 CAR-T) have an enhanced antitumor activity against established tumors. Compared to IL2-polarized (T1) cells, T9 CAR-T cells secrete IL9 but little IFN-γ, express central memory phenotype and lower levels of exhaustion markers, and display robust proliferative capacity. Consequently, T9 CAR-T cells mediate a greater antitumor activity than T1 CAR-T cells against established hematologic and solid tumors in vivo. After transfer, T9 CAR-T cells migrate effectively to tumors, differenti","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Nov","modification":"2025-04-27T00:33:38.597Z","creation":"2021-02-20T00:27:13Z"},"accession":"S-EPMC7677397","cross_references":{"pubmed":["33214555"],"doi":["10.1038/s41467-020-19672-2"]}}